Here, we focus on the important issue of the specificity of aspirin's protective effects, as observed in epidemiological studies, and we set out to determine whether cell-type specific effects on the NFκB signalling pathway reflect the differential protective effects of aspirin in different cancer types. The gene discussed is NFKB1; the disease is cancer.